Literature DB >> 27031368

Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas.

Esther Conde1,2, Susana Hernandez1, Mario Prieto1,2, Rebeca Martinez1, Fernando Lopez-Rios1,2.   

Abstract

The development of several ALK inhibitors means that the importance of accurately identifying ALK-positive lung cancer has never been greater. Therefore, it is crucial that ALK testing assays become more standardized. The aim of this review is to comment on the recently FDA-approved VENTANA ALK (D5F3) Companion Diagnostic (CDx) Assay. This kit provides high sensitivity and specificity for the detection of ALK rearrangements and seamless integration into the laboratory workflow, with a fully automated analytical phase and fast interpretation. The use of controls increases the sensitivity and specificity and a dichotomous scoring approach enhances reproducibility.

Entities:  

Keywords:  ALK; FISH; IHC; companion diagnostic; lung carcinoma

Mesh：

Substances：

Year:  2016        PMID： 27031368     DOI： 10.1586/14737159.2016.1172963

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN： 1473-7159            Impact factor:   5.225


  22 in total

Review 1.  Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.

Authors:  Xiaomin Niu; Jody C Chuang; Gerald J Berry; Heather A Wakelee
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 2.  Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.

Authors:  Emily B Ehlerding; Piotr Grodzinski; Weibo Cai; Christina H Liu
Journal:  ACS Nano       Date:  2018-03-01       Impact factor: 15.881

3.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.

Authors:  Jason N Rosenbaum; Ryan Bloom; Jason T Forys; Jeff Hiken; Jon R Armstrong; Julie Branson; Samantha McNulty; Priya D Velu; Kymberlie Pepin; Haley Abel; Catherine E Cottrell; John D Pfeifer; Shashikant Kulkarni; Ramaswamy Govindan; Eric Q Konnick; Christina M Lockwood; Eric J Duncavage
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

4.  Comment on "ALK is a therapeutic target for lethal sepsis".

Authors:  Rafael B Blasco; Enrico Patrucco; Ines Mota; Wei-Tien Tai; Roberto Chiarle
Journal:  Sci Transl Med       Date:  2018-12-12       Impact factor: 17.956

5.  Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.

Authors:  Ying Ding; Chang Sun; Wei Su; Chen Miao; Xiao He; Jin-Song Wang; Zhi-Hong Zhang
Journal:  Virchows Arch       Date:  2022-05-28       Impact factor: 4.535

Review 6.  The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.

Authors:  Yating Chen; Wenjie Guo; Junsheng Fan; Yuqing Chen; Xiaoli Zhang; Xin Chen; Peng Luo
Journal:  Cancer Manag Res       Date:  2017-12-07       Impact factor: 3.989

7.  Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Authors:  Ibiayi Dagogo-Jack; A Rose Brannon; Lorin A Ferris; Catarina D Campbell; Jessica J Lin; Katherine R Schultz; Jennifer Ackil; Sara Stevens; Leila Dardaei; Satoshi Yoda; Harper Hubbeling; Subba R Digumarthy; Markus Riester; Aaron N Hata; Lecia V Sequist; Inga T Lennes; A John Iafrate; Rebecca S Heist; Christopher G Azzoli; Anna F Farago; Jeffrey A Engelman; Jochen K Lennerz; Cyril H Benes; Rebecca J Leary; Alice T Shaw; Justin F Gainor
Journal:  JCO Precis Oncol       Date:  2018-01-23

8.  Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.

Authors:  Sebastian Mondaca; Emily S Lebow; Azadeh Namakydoust; Pedram Razavi; Jorge S Reis-Filho; Ronglai Shen; Michael Offin; Hai-Yan Tu; Yonina Murciano-Goroff; Chongrui Xu; Alex Makhnin; Andres Martinez; Nick Pavlakis; Stephen Clarke; Malinda Itchins; Adrian Lee; Andreas Rimner; Daniel Gomez; Gaetano Rocco; Jamie E Chaft; Gregory J Riely; Charles M Rudin; David R Jones; Mark Li; Tristan Shaffer; Seyed Ali Hosseini; Caterina Bertucci; Lee P Lim; Alexander Drilon; Michael F Berger; Ryma Benayed; Maria E Arcila; James M Isbell; Bob T Li
Journal:  Lung Cancer       Date:  2021-07-17       Impact factor: 6.081

9.  Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.

Authors:  David R Hout; Brock L Schweitzer; Kasey Lawrence; Stephan W Morris; Tracy Tucker; Rosetta Mazzola; Rachel Skelton; Frank McMahon; John Handshoe; Mary Lesperance; Aly Karsan; David L Saltman
Journal:  Cancers (Basel)       Date:  2017-08-01       Impact factor: 6.639

Review 10.  ALK-rearrangement in non-small-cell lung cancer (NSCLC).

Authors:  Xue Du; Yun Shao; Hai-Feng Qin; Yan-Hong Tai; Hong-Jun Gao
Journal:  Thorac Cancer       Date:  2018-02-28       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.